LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | SB590885 | 10.0 | uM | LJP5 | 72 | hr | 868 | 706 | 3486 | 0.2026 | -0.0618 |
| MDA-MB-231 | PIK-93 | 10.0 | uM | LJP5 | 72 | hr | 868 | 1450 | 3486 | 0.4160 | 0.2224 |
| MDA-MB-231 | KIN001-043 | 10.0 | uM | LJP6 | 72 | hr | 868 | 1857 | 3486 | 0.5327 | 0.3778 |
| MDA-MB-231 | Alpelisib | 10.0 | uM | LJP5 | 72 | hr | 868 | 2084 | 3486 | 0.5979 | 0.4646 |
| MDA-MB-231 | Luminespib | 10.0 | uM | LJP5 | 72 | hr | 868 | 951 | 3486 | 0.2729 | 0.0318 |
| MDA-MB-231 | A443654 | 10.0 | uM | LJP6 | 72 | hr | 868 | 661 | 3486 | 0.1897 | -0.0790 |
| MDA-MB-231 | OSI-027 | 10.0 | uM | LJP6 | 72 | hr | 868 | 1656 | 3486 | 0.4752 | 0.3012 |
| MDA-MB-231 | XMD11-85h | 10.0 | uM | LJP6 | 72 | hr | 868 | 1495 | 3486 | 0.4288 | 0.2394 |
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 868 | 526 | 3486 | 0.1510 | -0.1305 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 868 | 756 | 3486 | 0.2169 | -0.0427 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 868 | 944 | 3486 | 0.2709 | 0.0291 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 868 | 924 | 3486 | 0.2652 | 0.0216 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 868 | 2241 | 3486 | 0.6428 | 0.5243 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 868 | 661 | 3486 | 0.1896 | -0.0791 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 868 | 1363 | 3486 | 0.3910 | 0.1890 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 868 | 617 | 3486 | 0.1772 | -0.0957 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 868 | 402 | 3486 | 0.1155 | -0.1778 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 868 | 586 | 3486 | 0.1683 | -0.1075 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 868 | 469 | 3486 | 0.1345 | -0.1524 |
| MDA-MB-231 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 868 | 2866 | 3486 | 0.8222 | 0.7633 |
| MDA-MB-231 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 868 | 2329 | 3486 | 0.6680 | 0.5580 |
| MDA-MB-231 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 868 | 1730 | 3486 | 0.4963 | 0.3293 |
| MDA-MB-231 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 1086 | 3486 | 0.3117 | 0.0835 |
| MDA-MB-231 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 939 | 3486 | 0.2695 | 0.0273 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 868 | 633 | 3486 | 0.1818 | -0.0895 |